BioRestorative Therapies, Inc. (BRTX) reported a net loss of $14.2 million for the fiscal year ending December 31, 2025, compared to a net loss of $9.0 million in 2024. The company's revenues decreased to $359,700 from $401,000 in the previous year, primarily due to a decline in royalty revenue from a sublicense agreement. Operating expenses rose significantly, with research and development costs increasing by 51% to $10.1 million, driven by expenses related to the ongoing Phase 2 clinical trial of its lead product candidate, BRTX-100, aimed at treating chronic lower back pain.
The company’s financial position has raised concerns about its ability to continue as a going concern, as it reported a working capital deficit of $586,029 as of December 31, 2025. BioRestorative has indicated that it will require substantial additional funding to support its clinical trials and operational needs. In 2025, the company raised approximately $2 million through an at-the-market offering and $1.1 million from a registered direct offering. In February 2026, it completed a public offering that generated gross proceeds of $5 million.
Strategically, BioRestorative is advancing its Disc/Spine Program, with BRTX-100 receiving Fast Track designation from the FDA, which may expedite its clinical development. The company is also developing its ThermoStem Program, targeting metabolic disorders, and has secured multiple patents related to both programs. In 2025, BioRestorative expanded its workforce, hiring key personnel to enhance its technology commercialization and global operations.
Operationally, the company has faced challenges, including a significant reliance on a limited number of customers for its revenue streams. As of March 23, 2026, BioRestorative had 25,478,170 shares of common stock outstanding and was notified by Nasdaq of its non-compliance with the minimum bid price requirement, which could lead to delisting if not resolved. The company is actively monitoring its stock price and considering options to regain compliance, including a potential reverse stock split.
Looking ahead, BioRestorative anticipates continued losses as it executes its development plans and seeks additional financing. The company remains focused on advancing its clinical trials and expanding its product offerings, while navigating the complexities of regulatory approvals and market competition.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. develops cell-based therapeutic products primarily using adult stem cells for regenerative medicine. Its core programs target chronic lower back pain via BRTX-100, an autologous mesenchymal stem cell therapy for disc and spine conditions, and metabolic disorders through the ThermoStem platform using brown adipose-derived stem cells. The company also operates a biocosmeceuticals segment offering cell-based aesthetic products. It focuses on minimally invasive treatments with proprietary technology and clinical-grade manufacturing.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.